From its Potomac headquarters, IGC Pharma develops investigational therapies and AI tools for Alzheimer’s disease and related dementias. Its lead candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer’s dementia, while the company’s MINT-AD and aha™ platforms apply artificial intelligence to risk prediction and research-data harmonization. IGC Pharma operates an integrated international organization with manufacturing and processing in Vancouver, Washington, clinical research in Colombia, and accounting and analytics in India.
FDA Investigational New Drug (IND) application
Registration
ClinicalTrials.gov Registration NCT05543681
Registration
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
P2D BioscienceP2D Bioscience is a specialty pharmaceutical company developing drug candidates for inflammatory disorders of the central nervous system, with a pipeline aimed at frontotemporal dementia, Alzheimer’s disease and ADHD. Its approach combines targeted phenotypic screening with transgenic preclinical models, while its management brings deep experience in neuroscience, toxicology and early-stage drug development. The company advances candidates through preclinical and early clinical studies before seeking partners for later development and commercialization.CINCINNATI, OH
Cerevia NeurosciencesCerevia Neurosciences is developing a closed-loop, fMRI-guided neuromodulation platform for dementia care, centered on its compact Ladybug™ Sanctuary unit. The company combines AI-driven personalization with integrated brain imaging to deliver non-invasive therapy in clinical and memory-care settings. Cerevia is a spin-out of the Weinberg Medical Holdings venture studio and holds more than 35 U.S. and international patents.ROCKVILLE, MD
Curia Global, IncFounded in Albany in 1991 as Albany Molecular Research, Curia is a global contract research, development and manufacturing organization serving pharmaceutical and biotechnology companies from drug discovery through commercial production. The company now operates an integrated network of more than 20 facilities across North America, Europe and India, with more than 3,000 professionals supporting small-molecule and biologics programs. Curia’s history includes discovery and development of the active pharmaceutical ingredient in Allegra and deep experience scaling complex APIs, sterile drug products and biologics.ALBANY, NY